论文部分内容阅读
目的:探讨用聚乙二醇干扰素治疗慢性丙型病毒性肝炎的临床效果。方法 :对2013年3月~2014年9月期间我院收治的140例慢性丙型病毒性肝炎患者的临床资料进行回顾性研究。我们将这140例患者随机分为观察组和对照组,每组各有70例患者。为对照组患者使用利巴韦林进行治疗,为观察组患者使用聚乙二醇干扰素进行治疗。治疗结束后,比较两组患者在进行治疗前后血清TB、ALT、AST及HA、IVC、LN、PCⅢ的水平。结果 :在进行治疗前,两组患者血清TB、ALT、AST及HA、IVC、LN、PCⅢ的水平相比差异均不具有显著性(P>0.05)。进行治疗后,两组患者血清TB、ALT、AST及HA、IVC、LN、PCⅢ的水平均有明显下降,且观察组患者血清TB、ALT、AST及HA、IVC、LN、PCⅢ的水平均明显低于对照组患者,二者相比差异具有显著性(P<0.05)。结论:用聚乙二醇干扰素对慢性丙型病毒性肝炎患者进行治疗的效果显著。此治疗方法值得在临床上推广应用。
Objective: To investigate the clinical efficacy of pegylated interferon in the treatment of chronic hepatitis C virus. Methods: The clinical data of 140 patients with chronic hepatitis C treated in our hospital from March 2013 to September 2014 were retrospectively studied. We randomly assigned the 140 patients to observation and control groups, each with 70 patients in each group. The patients in the control group were treated with ribavirin and the patients in the observation group were treated with pegylated interferon. After the treatment, the levels of serum TB, ALT, AST, HA, IVC, LN and PCIII in both groups before and after treatment were compared. Results: Before treatment, the levels of serum TB, ALT, AST, HA, IVC, LN and PCⅢ in the two groups were not significantly different (P> 0.05). After treatment, the levels of serum TB, ALT, AST and HA, IVC, LN and PCⅢ in both groups were significantly decreased, and the levels of serum TB, ALT, AST and HA, IVC, LN and PCⅢ in the observation group were significantly The difference between the two groups was significant (P <0.05). Conclusion: Pegylated interferon is effective in treating chronic hepatitis C patients. This treatment is worth promoting in clinical application.